Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation
Authors:
- Joaquin CabezasJCJoaquin Cabezas
- Antonio AguileraAAAntonio Aguilera
- Federico GarcíaFGFederico García
- Raquel Domínguez-HernándezRDRaquel Domínguez-Hernández
- Araceli Casado-GómezACAraceli Casado-Gómez
- Nataly Espinoza-CámacNENataly Espinoza-Cámac
- Miguel Ángel CasadoMCMiguel Ángel Casado
- Javier CrespoJCJavier Crespo
Open Access
Abstract
In 2022, scientific societies agreed on a document with recommendations for a comprehensive diagnosis of viral hepatitis (B, C, and D). The aim was to evaluate the situation in Spain regarding the comprehensive diagnosis of viral hepatitis in a single blood draw before it is recommended. A panel of experts prepared a structured survey directed at hospitals (public or private with teaching accreditation) with ≥200 beds (sent 20 October 2022, closed 1 December 2022). The response rate was 61% (79/129; 52 hospitals with >500 beds). Among the participating hospitals, all could perform tests for HBsAg, anti-HCV, and HIV serology; 94% could perform PCR testing for HCV, 63% could test for anti-HDV, and 28% could test for HDV-RNA (67% [53/79] outsourced this testing). Point-of-care (POC) testing availability was low (24%), with 84% of these tests being supervised by the reference microbiological laboratory and the results being registered in the patients’ medical history. Ninety percent of the centers carried out the diagnosis in a single step (99% HCV, 70% HBV, 48% HDV, and 44% HBV-HDV). In addition, 77% used some communication strategy when an active infection was encountered (100% HCV, 49% HBV, and 31% HDV). Only 20% had an automated system for scheduling a specialist physician appointment. Most hospitals had the means for a comprehensive diagnosis of viral hepatitis in a single sample, but <50% could test for HBV/HDV. Alerts for continuity of care were available for HCV, but not HBV or HDV. POC device implementation is important for decentralized testing.Keywords
Funding Information
- Gilead (IN-ES-980-6538, IDIVAL 2022-8959)
- FOCUS program (Gilead group) (IN-ES-980-6538, IDIVAL 2022-8959)
This publication has 23 references indexed in Scilit:
- Combined “Test and Treat” Campaigns for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C: A Systematic Review to Provide Evidence to Support World Health Organization Treatment GuidelinesOpen Forum Infectious Diseases, 2024
- The path to successful hepatitis C elimination in SpainNature Reviews Gastroenterology & Hepatology, 2023
- The evaluation of people suspected of sexually transmitted diseases requires tools for the comprehensive diagnosis of viral hepatitis and HIVJournal of Hepatology, 2023
- Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analíticaGastroenterología y Hepatología, 2022
- Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis DJHEP Reports, 2022
- Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry reviewScientific Reports, 2021
- Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en EspañaEnfermedades Infecciosas y Microbiología Clínica, 2021
- The global prevalence of hepatitis D virus infection: Systematic review and meta-analysisJournal of Hepatology, 2020
- Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus InfectionThe Journal of Infectious Diseases, 2019
- El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorarEnfermedades Infecciosas y Microbiología Clínica, 2019